ARVN (Arvinas) Valuation Rank


ARVN Arvinas Inc ARVN
66 GF Score
Price $8.39
GF Value $12.22
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arvinas Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Arvinas Valuation Rank Related Terms

ARVN
66GF Score
Arvinas Inc ARVN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arvinas (ARVN) Overvalued in 2026?

Based on GuruFocus' analysis, Arvinas stock appears to be undervalued. The current stock price of $8.39 is trading 31.3% below its estimated GF Value™ of $12.22. GuruFocus considers Arvinas to be Possible Value Trap.

Key valuation signals for ARVN:

  • Valuation Rank:
  • GF Value™: $12.22 vs. price of $8.39 (31.3% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arvinas Business Description

Address 395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
66GF Score

Get the complete analysis for ARVN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.39
Price
$12.22
GF Value